Alaunos Therapeutics, Inc.TCRTEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| MSD Partners, L.P. | 6.30% | 101.0K | ▼ -2.90pp | 2024-11-14 |
| NOS. OF ABOVE PERSONS | 1.66% | 4.0M | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.